Compare Flagstar Bank NA (FLG) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flagstar Bank NA vs Nuvalent Inc — how do they compare? Flagstar Bank NA trades at $15.36 (market cap $6.26B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Nuvalent Inc is the larger of the two by market cap, and Flagstar Bank NA pays a 0.27% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| FLG | NUVL | |
|---|---|---|
Market Cap | $6.26B | $9.81B |
Sector | Financials | Technology |
52-Week High | $15.28 | $123.96 |
52-Week Low | $10.72 | $72.16 |
Dividend Yield | 0.27% | — |
Enterprise Value | — | $8.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Flagstar Bank (FLG) trades at $15.36, up 2.67% today, with a bullish technical signal from moving averages. The stock shows improving fundamentals, with two consecutive quarterly EPS beats and a positive Q1 2026 net income. The company is executing a turnaround, highlighted by a proprietary technology transformation and a credit rating upgrade. The price trades below the consensus target of $17.05, with a price-to-book ratio of 0.82 suggesting potential undervaluation.
The outlook is cautiously optimistic, supported by analyst consensus and recent profitability. Key opportunities include continued operational improvement and capital returns. Risks involve the ongoing turnaround execution, net negative cash flow, and sensitivity to interest rates. The stock presents a value proposition if the bank sustains its recovery trajectory.
Nuvalent (NUVL) trades at $123.96, unchanged on the day, with a P/B ratio of 8.35 and negative profitability metrics. The stock is technically bullish based on moving averages, though oscillators are neutral. Recent news highlights GSK's proposed acquisition of Nuvalent for $124 per share, totaling $10.6 billion, announced on June 9, 2026 (Reuters). Earnings have been mixed, with two misses and one beat in the last three quarters.
The acquisition by GSK provides a near-term price floor but limits upside. Risks include ongoing financial losses and shareholder litigation questioning deal fairness. Analyst sentiment is mixed with 42% buy ratings. The stock's outlook hinges on deal completion, with fundamental challenges persisting until closure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
